The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Latest developments in lymphoma at ASH 2020
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, highlights the latest developments in lymphoma presented at ASH 2020. More specifically, prof. Ansell underlines novel analysis into different subsets of lymphoma, as well as promising new agents within the categories of antibody-drug conjugates and bispecific antibodies. New agents are being tested in R/R patients with the hope that, in combination with front-line treatment, overall patient outcomes will improve. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Research funding: Bristol Myers Squibb, Seattle Genetics, ADC Therapeutics, Affimed, Trillium, AI Therapeutics, Regeneron
